Factors Associated With Decision Making In the Second-Line Treatment of Patients With Advanced/Metastatic Gastrointestinal Cancers
Podcast 1: Managing GEJ Cancers in the community setting

Questions marked with a * are required
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
Christine is a 68 year-old woman who presents with a mass at GE junction and diffuse liver metastases, who is started on first-line therapy. At her 3 month visit, she is noted to have progression of her metastases, and you start the discussion of second-line therapy options with her. Which of the following statements are true?
In order to maximize Christine’s outcome, you recommend FOLFIRI/ramucirumab as her second-line therapy. What do you tell her with regard to clinical practice guidelines?
Powered by QuestionPro